Multiple Mechanisms Affect the Clopidogrel Response  by Siasos, Gerasimos et al.
**
D
U
O
S
E
R
1
2
3
4
5
6
7
R
W
C
n
f
f
a
r
p
l
r
r
q
w
r
d
p
m
f
t
r
e
a
e
f
*
M
H
I
R
H
E
J
A
J
*
L
A
L
t
E
R
1
2
3
M
A
W
o
a
p
e
a
m
c
m
w
l
m
c
p
c
k
m
w
o
m
t
p
C
(
900 Correspondence JACC Vol. 53, No. 10, 2009
March 10, 2009:898–903Lionel H. Opie, MD, DPhil, FRCP, FACC
Director, Hatter Cardiovascular Research Institute
epartment of Medicine
niversity of Cape Town Faculty of Health Sciences
bservatory 7925
outh Africa
-mail: Lionel.opie@uct.ac.za
doi:10.1016/j.jacc.2008.10.059
EFERENCES
. Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in
obese patients with type 2 diabetes mellitus decreases myocardial
triglyceride content and improves myocardial function. J Am Coll
Cardiol 2008;52:1006–12.
. Opie LH. Metabolic syndrome. Circulation 2007;115:e32–5.
. Shipp J, Opie LH, Challoner DR. Fatty acid and glucose metabolism in
the perfused heart. Nature 1961;189:1018–9.
. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle.
Its role in insulin sensitivity and the metabolic disturbances of diabetes
mellitus. Lancet 1963;1:785–9.
. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of a sustained
reduction in plasma free fatty acid concentration on intramuscular
long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic
patients. Diabetes 2005;54:3148–53.
. Taegtmeyer H, Harmancey R. Virchow’s metamorphosis revealed
triglycerides in the heart. J Am Coll Cardiol 2008;52:1013–4.
. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid
accumulation in the failing human heart resembles the lipotoxic rat
heart. FASEB J 2004;18:1692–700.
eply
e thank Dr. Opie for his comment on our recent publication (1).
aloric restriction is a powerful tool to reverse at least some of the
egative effects induced by obesity in diabetic patients.
The hypothesis that the effects of the metabolic syndrome arise
rom high levels of circulating fatty acids and cytokines derived
rom (visceral) adipose tissue (2) is indeed supported by our data,
lthough one has to use caution in considering this a causal
elationship, solely based on the present results.
On the other hand, it was recently shown, in another group of
atients with type 2 diabetes, that plasma free fatty acids are, at
east to some extent, involved in the effects of short-term caloric
estriction on the heart (3). We showed that short-term caloric
estriction induced increased levels of free fatty acids and conse-
uently, myocardial triglycerides accumulated. This was associated
ith a change in diastolic function. Interestingly, when this caloric
estriction was combined with administration of the antilipolytic
rug acipimox, these changes were not observed. These results
rovide circumstantial evidence for the relevance of fatty acids in
yocardial triglyceride accumulation and changes in diastolic
unction in this particular group of patients, perfectly in line with
he hypothesis stating the relevance of fatty acids and cytokines
eleased by adipose tissue.
We therefore generally agree with Dr. Opie that our results are
xciting, and they underline the high potential of treatments
iming to decrease adipose tissue compartments to reverse the
ffects of metabolic disease on the heart, whether associated with
atty acids released from adipose tissue or not. cSebastiaan Hammer, MSc
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ultiple Mechanisms
ffect the Clopidogrel Response
e read with interest the paper by Ang et al. (1) in a previous issue
f the Journal. The purpose of the study was to identify factors
ssociated with lower platelet inhibition (PI) with clopidogrel in
atients with cardiovascular disease. Their results showed that
levated plasma fibrinogen 375 mg/dl is a unique factor associ-
ted with lower PI in diabetic patients, whereas increased body
ass index remains independently associated with lower PI after
lopidogrel therapy. They also identify the presence of diabetes
ellitus as a factor associated with lower PI. However, this finding
as only significant in the presence of an elevated serum fibrinogen
evel. No other statistical association with PI was found in the
ultiple variable model.
Although these findings are interesting, other factors involving
lopidogrel response have not been completely evaluated. For exam-
le, the impact of genetic polymorphisms or other genetic factors on
lopidogrel response has not been evaluated in the study. It is well
nown that P2Y12 receptor inhibition is implemented by an active
etabolite of clopidogrel. Therefore, genetic variants of enzymes
ithin the metabolic pathways (P450 enzymes) or downstream targets
f the active metabolite (P2Y, platelet glycoproteins IIb/IIIa and Ia)
ight affect clopidogrel response. Moreover, the metabolic activity of
he P450 enzymes varies considerably among individuals. Genetic
olymorphisms of the cytochrome P450 isoenzymes such as
YP3A4*1B (rs2740574), CYP3A5*3 (rs776746), and CYP2C19*2
rs4244285) have been implicated to modulated individual response to
lopidogrel (2). However, only CYP2C19*2 (SNP rs4244285, AA
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March 10, 2009:898–903enotype) polymorphism association with variable clopidogrel re-
ponse has been validated in both healthy and acute coronary
yndrome individuals (3). The association of platelet glycoproteins
IIa and P2Y12 receptor polymorphisms with clopidogrel variable
esponse has not been confirmed in previous studies (4), and it should
lso be examined in the study by Ang et al. (1).
Finally, other mechanisms, such as cellular factors (accelerated
latelet turnover, reduced CYP3A metabolic activity, increased
DP exposure, up-regulation of P2Y pathways), or clinical factors
noncompliance, underdosing, poor absorption) may cause subop-
imal clopidogrel response.
This interesting study by Ang et al. (1) sheds some light on
echanisms underlying reduced response of platelets to the anti-
ggregatory effect of clopidogrel. Although the limited number of
atients with lower inhibition of platelet reactivity by clopidogrel
akes the findings exploratory, further studies with a larger cohort
f patients are needed to elucidate the multiple mechanisms
nvolving clopidogrel response.
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eply
e appreciate the comments by Dr. Siasos and colleagues in
esponse to our recent study published in the Journal (1). We agree
hat many factors are associated with variable platelet reactivity
esponse to clopidogrel, including drug absorption, generation of
ctive drug metabolites, cytochrome P450 isoenzyme variants,
rug–drug interactions, and P2Y12 receptor polymorphisms. In
articular, significant efforts have been directed at clarifying the
ole of hepatic cytochrome P450 isoenzymes, including CYP3A4,
YP3A5, and CYP2C19 polymorphisms. Although there are
onflicting data, a significant role of CYP3A4*1B or CYP3A5*3
olymorphisms in accounting for lower platelet inhibition (PI)
ith clopidogrel seems unlikely (2). However, CYP2C19 geno-
yping allows identification of 90% of poor clopidogrel metabo-izers (3), and carriers of the CYP2C19*2 mutant allele seem to
ave an attenuated PI response when presenting with an acute
oronary syndrome (ACS) or undergoing an elective percutaneous
oronary intervention (2,4).
The goal of our study was to determine the role of clinical and
iochemical factors known to affect platelet reactivity on the PI
ttained with clopidogrel in patients with cardiovascular disease
1). Elevated serum fibrinogen, diabetes mellitus, and higher body
ass index were associated with a lower PI. A significant interac-
ion was also observed between diabetes and elevated fibrinogen,
ccounting for at least one mechanism for the poor response of
iabetics to clopidogrel. As acknowledged in the Study Limita-
ions section of our article (1), we did not assess patients for genetic
olymorphisms. In patients with ACS treated with clopidogrel,
rere et al. (2) found a significant association between being a
arrier of the CYP2C19*2 mutant allele and higher platelet
eactivity. Nevertheless, higher body mass index remained inde-
endently associated with higher post-treatment platelet reactivity.
alek et al. (5) have shown that ACS patients with polymor-
hisms for both the P2Y12 platelet receptor and CYP2C19 are at
n increased risk of excess platelet activity after clopidogrel
reatment, and have a higher risk of ischemic cardiovascular events.
owever, no known data suggest that the role of the clinical and
iochemical markers that we have identified would be altered in
he presence or absence of a P2Y12 receptor or CYP2C19
olymorphism. Future studies should expand on our findings by
etermining P2Y12 and glycoprotein IIIa platelet cell-surface
eceptor, and CYP450 isoenzyme genotypes, and evaluating their
nteractions with the clinical and biochemical markers of poor
latelet inhibition with clopidogrel.
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